Skip to main content
Journal cover image

Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial.

Publication ,  Journal Article
Nouhravesh, N; Greene, SJ; Clare, R; Wojdyla, D; Anstrom, KJ; Velazquez, E; Pitt, B; Mentz, RJ; Psotka, MA
Published in: Eur J Heart Fail
February 2025

AIMS: The TRANSFORM-HF trial found no difference in clinical outcomes between torsemide versus furosemide after hospitalization for heart failure. This analysis aimed to assess the impact of diuretic dosing on the primary and secondary clinical outcomes. METHODS AND RESULTS: This post-hoc analysis of TRANSFORM-HF categorized patients into three groups by discharge diuretic dose: (1) ≤40 mg, (2) >40-80 mg, and (3) >80 mg of furosemide equivalents. The associations between discharge dose and 12-month clinical events, and change in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), were assessed. Overall, 2379 patients were included, aged 65 years (interquartile range 56-75), 883 (37.1%) women, and 812 (34.2%) Black. Furosemide had adjusted hazard ratios (aHR) for all-cause mortality of 1.21 (95% confidence interval [CI] 0.91-1.59) for discharge dose group 2 and 1.40 (95% CI 1.04-1.88) for group 3, compared with group 1. For torsemide, aHRs were 1.74 (95% CI 1.32-2.30) for group 2 and 1.58 (95% CI 1.14-2.19) for group 3. No evidence of heterogeneity for the association between increased mortality and higher dose was found by loop diuretic type (pinteraction = 0.17). Higher doses of furosemide and torsemide were associated with increased risk of all-cause hospitalization and the composite of all-cause mortality and hospitalization, without evidence of heterogeneity by loop diuretic type (pinteraction > 0.2). Changes in KCCQ-CSS from baseline at 12 months was similar across dose groups for both drugs. CONCLUSION: Following hospitalization for heart failure, higher loop diuretic dosing was independently associated with worse clinical and patient-reported outcomes. The correlation between higher loop diuretic dose and outcomes was consistent, regardless of loop diuretic used.

Duke Scholars

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

February 2025

Volume

27

Issue

2

Start / End Page

317 / 324

Location

England

Related Subject Headings

  • Treatment Outcome
  • Torsemide
  • Stroke Volume
  • Sodium Potassium Chloride Symporter Inhibitors
  • Middle Aged
  • Male
  • Humans
  • Hospitalization
  • Heart Failure
  • Furosemide
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nouhravesh, N., Greene, S. J., Clare, R., Wojdyla, D., Anstrom, K. J., Velazquez, E., … Psotka, M. A. (2025). Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial. Eur J Heart Fail, 27(2), 317–324. https://doi.org/10.1002/ejhf.3458
Nouhravesh, Nina, Stephen J. Greene, Robert Clare, Daniel Wojdyla, Kevin J. Anstrom, Eric Velazquez, Bertram Pitt, Robert J. Mentz, and Mitchell A. Psotka. “Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial.Eur J Heart Fail 27, no. 2 (February 2025): 317–24. https://doi.org/10.1002/ejhf.3458.
Nouhravesh N, Greene SJ, Clare R, Wojdyla D, Anstrom KJ, Velazquez E, et al. Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial. Eur J Heart Fail. 2025 Feb;27(2):317–24.
Nouhravesh, Nina, et al. “Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial.Eur J Heart Fail, vol. 27, no. 2, Feb. 2025, pp. 317–24. Pubmed, doi:10.1002/ejhf.3458.
Nouhravesh N, Greene SJ, Clare R, Wojdyla D, Anstrom KJ, Velazquez E, Pitt B, Mentz RJ, Psotka MA. Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial. Eur J Heart Fail. 2025 Feb;27(2):317–324.
Journal cover image

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

February 2025

Volume

27

Issue

2

Start / End Page

317 / 324

Location

England

Related Subject Headings

  • Treatment Outcome
  • Torsemide
  • Stroke Volume
  • Sodium Potassium Chloride Symporter Inhibitors
  • Middle Aged
  • Male
  • Humans
  • Hospitalization
  • Heart Failure
  • Furosemide